Nordson Corporation’s Post

OUR portfolio company VVT Medical in the process of listing on the Toronto Stock Exchange DXI CAPITAL CORP. ANNOUNCES PROPOSED ACQUISITION OF VVT Medical MED LTD. AND EXITEAM ACQUISITION CORP. DXI Capital Corp. has entered into a non-binding letter of intent dated Nov. 22, 2023, with V.V.T. Med Ltd. (VVT), an Israeli corporation, and Exiteam Acquisition Corp. (EAC), a British Columbia corporation, pursuant to which DXI has agreed to acquire all of the issued and outstanding shares in the capital of VVT and EAC as well as all other issued securities of VVT and EAC upon the terms and conditions set out in a definitive agreement to be entered into by the parties. The proposed transaction is expected to enable DXI to meet the initial listing requirements of the TSX Venture Exchange for the reactivation of DXI. Following the completion of the proposed transaction, DXI (the resulting issuer) will continue the business of VVT, being a new medical treatment for varicose veins, and will be listed on the TSX-V under the life sciences sector. Erez Tetro Oded Orgil 🎗️Robert Hodgkinson Sean Hodgins Dor Sneh

Some acquisition news with J&J! 📣 Please take a moment today to check out this article. It is an exciting read about Johnson & Johnson's agreement to acquire Shockwave Medical. https://lnkd.in/g6faRxrU

Medpace, rolling (stock up ~12% today, up ~62% past 12 months) 4Q2023 earnings release last night... - Revenue of $498.4 million in 4Q2023 increased 26.5% from revenue of $394.1 million for the comparable prior-year period - Net new business awards were $614.7 million in 4Q2023, representing an increase of 26.7% from net new business awards of $485.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x - Backlog as of December 31, 2023 increased 20.2% to $2,813.0 million from $2,339.6 million as of December 31, 2022 #cro #clinicaltrials #clinicaldevelopment #scdi

NeuroOne® (Nasdaq: NMTC) Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update. Dave Rosa, CEO of NeuroOne, commented, “We made excellent progress this quarter across multiple fronts. Revenue growth continued regarding our sEEG product line as new customer sites were added by Zimmer Biomet. We also initiated the limited commercial launch of the OneRF™ Ablation System, an exciting accomplishment given we are the first company to receive FDA 510(k) clearance to market this novel technology in the United States. Customer interest has been strong and we believe the OneRF™ Ablation System, with combination diagnostic and therapeutic functionality, has the capability to create a paradigm shift in neurosurgical procedures. Moving forward, we will investigate other applications to leverage our ablation system. We continue to believe strongly in the market opportunity for our drug delivery system as we believe it has the potential to create a unique platform for both identifying the target area in the brain, delivering the pharmacologic agent and monitoring its performance.” Read the press release for more information here: https://lnkd.in/dqF3R7r5 #N1MTC #NeuroOne #businessupdate

🚀Huge news in the cardiac device space 💰Edwards Lifesciences continues its strategic expansion with two major acquisitions totalling $1.2 billion: 🫀 JenaValve Technology, Inc. Technology: Trilogy Heart Valve System for aortic regurgitation (potential FDA approval in late 2025) 📡 Endotronix: Cordella implantable pulmonary artery pressure sensor (FDA-approved) 💡 These acquisitions follow recent deals with Innovalve Bio Medical Ltd. and Affluent Medical, showcasing Edwards Lifesciences' commitment to innovation in structural heart therapies. The acquisitions align with Edwards Lifesciences' strategic shift towards structural heart disease, following the recently announced $4.2 billion sale of its critical care business to BD. #MedTech #StructuralHeart #TMVR #Acquisition

The future is bright for Digital Therapeutics to improve lives. But the path to mainstream adoption of DTx is filled with obstacles. 😔 DTx pioneer Ryan Douglas says the FDA generally clears digital therapeutics as medical devices, but doesn't allow them to make claims about treating specific conditions. And there's no reimbursement yet from insurers. Both need to happen to create a sustainable market. Overcoming these challenges won't be easy. But the payoff makes it well worth the effort. Gain more insights at: https://lnkd.in/gj__4tbm #digitaltherapeutics #DTx #futureofhealth

SWISSMEDIC NEWS: Ensuring the supply of in vitro diagnostics and greater transparency in medical devices! Bern, August 14, 2024 - At its meeting on August 14, 2024, the Federal Department of Home Affairs informed the Federal Council that the transition periods for the new requirements for in-vitro diagnostics in Swiss law are to be adjusted and extended in linewith the EU regulation. In addition, the simplified labeling requirements for certain in- vitro diagnostics are to be continued indefinitely. The already enshrined obligation to register medical devices and in-vitro diagnostics in a central database is to come into force in 2026. #swissmedic #ivd #supply #switzerland #labelling #invitro #diagnostic

ViroMed Medical AG Plans to Acquire All Shares of ActivCell Group AG by Way of a Capital Increase Against Contribution in Kind with Exclusion of Subscription Rights - on #IndianConvention Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus strategically expand its product portfolio. To this end, the Company has today signed a term sheet with the owners of ActivCell Group AG and will immediately enter into further negotiations with the objective of concluding an agreement. With the acquisition of ActivCell Group AG, Viromed expands the treatment spectrum of its products with additional indications and expects an accelerated market launch in the European Union with its own cold plasma product series.   ActivCell Group […] - https://lnkd.in/gT7JSHWp 𝗖𝗹𝗶𝗰𝗸 𝘁𝗼 𝗝𝗼𝗶𝗻 𝘁𝗵𝗲 𝗙𝗮𝘀𝘁𝗲𝘀𝘁 𝗚𝗿𝗼𝘄𝗶𝗻𝗴 𝗡𝗲𝘁𝘄𝗼𝗿𝗸 - https://lnkd.in/gsYmD_BZ 𝗙𝗼𝗿 𝗗𝗲𝘁𝗮𝗶𝗹𝘀 𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗔𝗺𝗮𝗮𝗻 𝗧𝗮𝗾𝘃𝗶 𝗖𝗼𝗻𝗻𝗲𝗰𝘁 𝗼𝗻 𝗟𝗶𝗻𝗸𝗲𝗱𝗶𝗻 - https://lnkd.in/gVyPRrXb +91 7275859841

Johnson & Johnson’s Strategic Medtech Acquisitions: A Game Changer for Global and Indian Healthcare J&J's acquisition of Abiomed for $16.6 billion and Shockwave Medical for $13.1 billion has boosted its cardiovascular business, driving 26% growth in Q3 2024 and generating $2 billion in revenue. These deals align with J&J’s strategy to lead in high-growth cardiovascular markets, offsetting slower segments like orthopedics. This presents new opportunities for Indian pharmaceutical companies in research, manufacturing, and distribution of advanced devices. As the healthcare ecosystem in India evolves, partnerships with J&J could accelerate access to innovative cardiovascular technologies, benefiting patients and driving business growth.Johnson & Johnson #JohnsonAndJohnson #Medtech #CardiovascularHealth #Abiomed #ShockwaveMedical #HealthcareInnovation #IndiaPharma #MedicalDevices #BusinessGrowth #HealthcarePartnership #Cardiology #MergersAndAcquisitions #GlobalHealth #StrategicInvestments #PatientCare #IndianMarket #ResearchAndDevelopment #MedicalTechnology #InnovationLeadership #HealthcareEcosystem

It's no longer a question of if, but when! Johnson & Johnson (J&J) has announced a transformative $13.1 billion deal to acquire Shockwave Medical, bolstering its position in the cardiovascular medical-device market. The acquisition, priced at $335 per share in cash, represents a 4.7% premium over Shockwave's previous closing price. Founded in 2009, Shockwave specializes in innovative devices that treat calcium buildup in arteries, with a remarkable 50% revenue growth last year to $730 million. This strategic move expands J&J's MedTech business into high-growth cardiovascular segments, complementing its previous acquisitions like Abiomed and Laminar. J&J CEO Joaquin Duato highlighted that this acquisition aligns with their strategy to excel in the MedTech sector. Despite potential competition, including from Abbott Laboratories, this acquisition signifies a promising future for J&J and Shockwave's combined expertise. Stay tuned for more updates on this exciting development! Check out the article below! Darin W. White